Fusiomica sp. z o.o. is a biotechnology company specializing in the utilisation of protein engineering and AI in drug discovery. Founded by experienced pharma/biotech managers with strong Cambridge links and based in Kraków at the Małopolskie Centrum Biotechnologii UJ, we aim to bridge the Polish and Cambridge biotech environments.
Mark’s expertise in tackling complex drug discovery challenges, particularly in oncology and neuroscience, underpins his vision for this company. With over 15 years at AstraZeneca, Mark led the development of industry-leading protein engineering capability and cutting-edge biophysical and structural biology techniques (SPR, biomolecular NMR, HDX-MS). He also managed the AZ/MRC-LMB Blue Sky collaboration, which delivered over 40 research projects, two spin-out companies, and numerous high-impact publications. Prior AstraZeneca, he was a co-founder of Domainex, a company that has since become a successful player in the structure-based drug discovery. Mark invented combinatorial domain hunting technology and secured early-stage funding that laid the foundation for the company’s growth.
Work Experience:
Education:
Michał is a co-founder of our company, combining deep expertise in structural biology, protein engineering, and drug discovery. Before joining us, Michał served as VP and Head of Structure, Fragments, and Biophysics at Captor Therapeutics, where he led teams responsible for recombinant protein production, structural biology, and molecular modelling. His work contributed to multiple R&D projects, including EU-funded grants and external collaborations. Earlier in his career, Michał worked at AstraZeneca, supporting early drug discovery across oncology and other therapeutic areas. He played a key role in advancing multiple projects, including the development of the selective PARP1 inhibitor, saruparib (AZD5305), now in PhIII clinical trials. Michał is recognized for establishing innovative screening strategies and fostering research alliances with academia and industry.
Work Experience:
Education:
Our aim is to tackle the most challenging problems in drug discovery, leveraging novel technologies and prior experience from the most distinguished academic and commercial institutions.
For inquiries, please email us at: [email protected]